Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How effective are current therapies for acromegaly?

Pamela U Freda1

  • 1Department of Medicine, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY, USA. puf1@columbia.edu

Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society
|August 14, 2003
PubMed
Summary

Current acromegaly treatments include surgery, radiation, and medications like somatostatin analogues. While effective, achieving normalized hormone levels and tumor control often requires multi-modality approaches for optimal patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective Observational Study of 118 Clinically Nonfunctioning Pituitary Adenomas.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2025
Same author

Pituitary incidentaloma: a Pituitary Society international consensus guideline statement.

Nature reviews. Endocrinology·2025
Same author

Acromegaly: diagnostic challenges and individualized treatment.

Expert review of endocrinology & metabolism·2025
Same author

Prospective, Longitudinal Study of Cancer Predictors and Rates in a New York City Cohort of 598 Patients With Acromegaly.

The Journal of clinical endocrinology and metabolism·2024
Same author

Impact of medical therapy for hormone-secreting Pituitary tumors on bone.

Pituitary·2024
Same author

Long-term Pegvisomant Therapy of Acromegaly: Effects on Bone Density, Turnover and Microstructure Using HRpQCT.

Journal of the Endocrine Society·2024

Area of Science:

  • Endocrinology
  • Neurosurgery
  • Oncology

Background:

  • Acromegaly is a hormonal disorder caused by excessive growth hormone (GH) production, leading to significant clinical manifestations.
  • Current therapeutic goals include normalizing GH and insulin-like growth factor-I (IGF-I) levels, reducing disease symptoms, and decreasing tumor size.
  • Therapies must also preserve pituitary function and minimize side effects.

Purpose of the Study:

  • To review and compare the efficacy and outcomes of current therapies for acromegaly.
  • To highlight the role of transsphenoidal surgery (TSS), radiotherapy (RT), and medical management (dopamine agonists, somatostatin analogues).
  • To discuss the challenges in achieving complete disease control and the need for multi-modality treatment.

Main Methods:

Related Experiment Videos

  • Review of existing literature on acromegaly treatment modalities.
  • Analysis of efficacy data for TSS, RT, dopamine agonists (bromocriptine, quinagolide, cabergoline), and somatostatin analogues (octreotide, lanreotide).
  • Evaluation of outcomes related to hormone normalization, tumor shrinkage, symptom improvement, and side effect profiles.

    • Main Results:

    • TSS is effective for microadenomas (80-90% IGF-I normalization) and macroadenomas (50-60%), especially for mass effect symptoms.
    • RT can normalize IGF-I but has a long lag time and risk of hypopituitarism; medical therapy is often adjunctive.
    • Somatostatin analogues are the most effective medical therapy, normalizing IGF-I in 48-66% of patients and reducing tumor size in ~30%.

    Conclusions:

    • Multi-modality therapy is frequently necessary to achieve comprehensive disease control in acromegaly.
    • Despite advances, current treatments may not fully achieve all therapeutic goals in many patients.
    • Optimizing treatment strategies remains crucial for managing acromegaly effectively.